ABSTRACT BACKGROUND Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance
.
Although the PARADIGM-HF (Prospective

Comparison of ARNI With ACEI to Determine
Impact on Global Mortality and Morbidity in Heart Failure) trial was not designed to address the prognostic value of changes in NPs, the large sample size, significant event rate, effectiveness of treatment strategy, frequency of NP measurements, and length of follow-up of PARADIGM-HF provide an opportunity to address issues that limited earlier reports (34, 35) . We analyzed data from PARADIGM-HF to determine: 1) whether and to what degree a change in NT-proBNP was associated with a change in morbidity and mortality rates in patients with HF with reduced ejection fraction (HFrEF); 2) whether treatment of HFrEF patients with sacubitril/valsartan lowered NT-proBNP below specific partition values more often than enalapril; and 3) whether the relationship between change in NT-proBNP and change in morbidity and mortality event rates was influenced by treatment.
METHODS
STUDY PATIENTS. The design and primary results of PARADIGM-HF were described previously (12) . The institutional review boards of 1,043 participating institutions (in 47 countries) approved the protocol, and all patients gave written informed consent. Patients had New York Heart Association functional class II to IV symptoms, an ejection fraction of #35%, and a BNP $150 pg/ml (or NT-proBNP $600 pg/ml), or if they had been hospitalized for HF within the previous 12 months, a BNP $100 pg/ml (or an NTproBNP $400 pg/ml) (12) . Patients taking any dose of angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and able to tolerate the equivalent of enalapril 10 mg daily for $4 weeks before screening, along with stable doses of a b-blocker (unless contraindicated or not tolerated) and a mineralocorticoid antagonist (if indicated), were included. Patients were excluded for a history of intolerance to ACE inhibitors or ARBs (12) . Values are n (%).
NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide.
SEE PAGE 2437
A Zile et al.
NT-proBNP in HFrEF D E C E M B E R 6 , 2 0 1 6 : 2 4 2 5 -3 6 Did not achieve NT-proBNP ≤ 1000 pg/ml Achieved NT-proBNP ≤ 1000 pg/ml Did not achieve NT-proBNP < 1000 pg/ml Achieved NT-proBNP ≤ 1000 pg/ml 287 263 174 74
Risk of primary endpoint after 1 month of randomization in patients with a baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) (V2/V2a) >1,000 pg/ml who had a reduction in NT-proBNP at 1 month after randomization (V7) versus those patients who did not achieve a reduction in NT-proBNP at 1 month after randomization. The risk at 3 yrs of follow-up was z50% less in those who achieved a NT-proBNP #1,000 pg/ml than in those who did not. Mean follow-up was 2.4 years. 
Among patients with NT-proBNP >1,000 pg/ml at baseline Values are n (%). *High ¼ NT-proBNP > 1,000 pg/ml; Low ¼ NT-proBNP #1,000 pg/ml. †OR for patients in the High-High group having a reduction of NT-proBNP that converted them to the High-Low group was twice as likely in those treated with sacubitril/valsartan versus those treated with enalapril (OR: 2.15); the OR of patients in the Low-Low group maintaining this low value of NT-proBNP and remaining in the Low-Low group was twice as likely in those treated with sacubitril/valsartan versus those treated with enalapril (OR: 2.50).
NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; OR ¼ odds ratio. ongoing studies (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) , but analyses were also performed using thresholds of #750 pg/ml and #500 pg/ml. For each of these analyses, only those patients with a baseline NT-proBNP >1,000 pg/ml were examined. However, all patients with paired samples at baseline and 1 month were used for the landmark analysis of threshold changes of 10%, 20%, 30%, 40%, and 50% reduction from baseline.
Next, based on NT-proBNP values at baseline and at 1 month, patients were grouped into 4 categories:
NT-proBNP #1,000 pg/ml at both baseline and 1 month (Low-Low group); NT-proBNP >1,000 pg/ml) at baseline and 1 month (High-High group); NTproBNP >1,000 pg/ml at baseline and #1,000 pg/ml at 1 month (High-Low group); and NT-proBNP #1,000 pg/ml at baseline and >1,000 pg/ml at 1 month (Low-High group). Kaplan-Meier curves and
Cox proportional hazards models were used to characterize risk of subsequent events in each group. In addition, among all patients, the HRs associated with attaining or not attaining specific relative reductions in NT-proBNP were estimated, with and without adjustment for the log-transformed baseline NT-proBNP value. We created mutually exclusive categories of relative NT-proBNP reduction and reported event rates for each group, in all patients, and then for each treatment group. Between-group comparisons were made with respect to randomized treatment and interactions between treatment and changes in NT-proBNP.
The association between relative changes in NTproBNP from baseline (using log 2 -transformed values) and differences in risk of subsequent events
was assessed with Cox proportional hazards models, indicates an HR of 1.00. Solid oblique line (± dashed lines) indicates the calculated HR for patient population studied (AE 95% CI). for patients with baseline NT-proBNP >1,000
versus #1,000 pg/ml are presented in Online Table 1. One month after randomization, 24% of the baseline elevated NT-proBNP levels had fallen to #1,000 pg/ml ( patients without a fall in NT-proBNP to #1,000 pg/ml at 1 month ( Figure 1 , Table 2 ). Similar lower rates of the primary event rate were seen in patients with NTproBNP >1,000 pg/ml at baseline when the 1-month partition value was set to a reduction in NT-proBNP of #750 and #500 pg/ml ( Table 2 ). In addition, the risk of a primary event was significantly lower when the decrease in NT-proBNP from baseline to 1 month after randomization was measured as a percent change; this analysis included all patients with a measured NT-proBNP at baseline and 1 month ( Table 1) .
Using a categorical analysis ( Similar results were seen when the partition value was set at a reduction in NT-proBNP #750
and #500 pg/ml (Table 1, Figure 5 ); a larger proportion of patients treated with sacubitril/valsartan achieved these reductions than enalapril-treated patients. A similar differential treatment effect on the changes in NT-proBNP, measured as a percent reduction from baseline to 1 month after randomization ( Table 1 ) and using the categorical analysis (Table 3) , was seen with sacubitril/valsartan versus enalapril. In each analysis, a reduction in NT-proBNP or maintenance of a low NT-proBNP occurred more frequently in patients treated with sacubitril/valsartan than enalapril.
EFFECT OF BASELINE AND CHANGE IN NT-proBNP LEVELS ON TREATMENT EFFECT OF SACUBITRIL/ VALSARTAN VERSUS ENALAPRIL AND THE PRIMARY
EVENT RATE. Although baseline NT-proBNP was predictive of subsequent events in both treatment arms, 
DISCUSSION
In this study, a change in plasma NT-proBNP was associated with a change in cardiovascular mortality and HF hospitalization rate in patients with HFrEF.
Whether NT-proBNP fell to less than a specific numeric value, decreased by a specific percentage from baseline, or changed from a higher to a lower value, these reductions were associated with a significantly lower rate of morbidity and mortality. Sacubitril/Valsartan is a first-in-class neprilysin, angiotensin receptor inhibitor that promotes vasodilation and reduces vasoconstriction (A). Effects of sacubitril/valsartan could be due to direct biochemical inhibition of neprilysin and the resultant biological effect on the determinants of natriuretic synthesis. By inhibiting neprilysin, sacubitril/valsartan reduces degradation of B-type natriuretic peptide (BNP), resulting in an increase in BNP (C) and other vasoactive peptides. This might decrease both preload and afterload through diuretic and cell signaling effects. Increases in BNP and other vasoactive peptides could reduce the stimulus for natriuretic peptide synthesis by acting on the determinants of its synthesis; this conclusion is supported by the observed decrease in NT-proBNP (B). Treatment with sacubitril/valsartan would be expected to both increase BNP and decrease NT-proBNP. (44) . However, GUIDE-IT will use a single NP partition value; the effects on outcomes will be examined in patients with a baseline >1,000 pg/ml who will be treated to target the decrease in NT-proBNP to #1,000 pg/ml. STUDY LIMITATIONS. The accuracy of the predictive value of a change in any biomarker is in part dependent on at least 2 factors that influence variability in that biomarker. These include analytic variability (imprecision of the test) and biological variability (expected variability within the subject over time).
Although data evaluating the percent change in NTproBNP required to reflect a real change are limited, 1 study of 43 patients with congestive HF (CHF) (45) and another of 23 CHF patients (46) estimated the reference change value could range from 50% to 80%.
In the current study, the change from baseline data in particular should therefore be interpreted in light of the influence of the biological variability known to be present in CHF patients.
CONCLUSIONS
We demonstrated that a change in NT-proBNP, independent of the treatment group, was associated with a change in the subsequent risk of cardiovascular mortality and HF hospitalization and that sacubitril/valsartan was twice as likely to cause a prognostically meaningful reduction in NT-proBNP as enalapril. Zile et al.
